

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

CD144 (VE-Cadherin) Antibody, FITC, REAfinity™

RRID:AB_2655151

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-100-742, RRID:AB_2655151

Antibody Information

URL: http://antibodyregistry.org/AB_2655151

Proper Citation: Miltenyi Biotec Cat# 130-100-742, RRID:AB_2655151

Target Antigen: CD144 (VE-Cadherin)

Host Organism: human

Clonality: recombinant

Comments: Discontinued: 8-2020; Applications: MACS Flow Cytometry

Antibody Name: CD144 (VE-Cadherin) Antibody, FITC, REAfinity™

Description: This recombinant targets CD144 (VE-Cadherin)

Target Organism: human

Clone ID: [REA199]

Antibody ID: AB_2655151

Vendor: Miltenyi Biotec

Catalog Number: 130-100-742

Record Creation Time: 20231110T034436+0000

Record Last Update: 20260831T180817+0000

Ratings and Alerts

No rating or validation information has been found for CD144 (VE-Cadherin) Antibody, FITC, REAfinity™.

Warning: Discontinued: 2021

Discontinued: 8-2020; Applications: MACS Flow Cytometry

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Luo Y, et al. (2026) CRISPR/Cas9 engineered and whole-genome characterized KIT D816V-mutant human iPSC lines. Stem cell research, 93, 103975.

Fernandez Vallone V, et al. (2025) Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene. Stem cell research, 90, 103886.

Lewis K, et al. (2025) Generation of ten human induced pluripotent stem cell lines (hiPSCs) from patients with and without Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Post Chemotherapy Cognitive Impairment (PCCI). Stem cell research, 84, 103674.

Ludwik KA, et al. (2025) Generation of two human induced pluripotent stem cell lines from Allan-Herndon-Dudley syndrome (AHDS) patients with SLC16A2:G401R or SLC16A2:H192R mutation. Stem cell research, 86, 103725.

Härting N, et al. (2025) Generation of hiPSC lines with fusion tagged thyroid hormone receptor ? isoforms to study isoform-specific actions of TR?1 and TR?2. Stem cell research, 86, 103720.

Ludwik KA, et al. (2025) Generation of an isogenic iPSC line via CRISPR correction of the POMC:W84X mutation for monogenic obesity modeling. Stem cell research, 87, 103786.

Ludwik KA, et al. (2025) Correction of the Allan-Herndon-Dudley syndrome-causing SLC16A2 mutation G401R in a patient derived hiPSC line. Stem cell research, 85, 103698.

Ludwik KA, et al. (2025) Generation of human induced pluripotent stem cell line from an obesity patient with POMC deficiency due to POMC:W84X mutation. Stem cell research, 88, 103814.

Ludwik KA, et al. (2024) Generation of THRB-GS(E125G_G126S) and THRB-KO human iPSC lines to study noncanonical thyroid hormone signalling. Stem cell research, 74, 103275.

Ludwik KA, et al. (2023) Generation of iPSC lines with SLC16A2:G401R or SLC16A2 knock out. Stem cell research, 73, 103256.

Jung HS, et al. (2021) SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. *Cell reports*, 34(7), 108758.

Cernoch J, et al. (2021) Generation of 20 human induced pluripotent stem cell lines from patients with focal segmental glomerulosclerosis (FSGS). *Stem cell research*, 54, 102406.

Hennig AF, et al. (2019) Generation of a human induced pluripotent stem cell line (BIHi002-A) from a patient with CLCN7-related infantile malignant autosomal recessive osteopetrosis. *Stem cell research*, 35, 101367.

Arias-Fuenzalida J, et al. (2019) Generation of human induced pluripotent stem cell lines from patients with selective IgA deficiency. *Stem cell research*, 41, 101613.

Arias-Fuenzalida J, et al. (2019) Generation of a human induced pluripotent stem cell line (PHAi003) from a primary immunodeficient patient with CD70 mutation. *Stem cell research*, 41, 101612.

Hu B, et al. (2016) Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. *Cell*, 167(5), 1281.